Brolucizumab after failure of aflibercept with photodynamic therapy in polypoidal choroidal vasculopathy: A case report
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER LTD
Autores
Citação
ARCHIVOS DE LA SOCIEDAD ESPANOLA DE OFTALMOLOGIA, v.98, n.12, p.713-717, 2023
Resumo
We describe one case of polypoidal choroidal vasculopathy with persistent subretinal fluid despite multiple treatment with intravitreal bevacizumab, ranibizumab and aflibercept, as well as aflibercept associated with photodynamic therapy. The patient reached complete resolution after intravitreal brolucizumab injection, but experienced recurrence of subretinal fluid 12 weeks after discontinuation. Brolucizumab might be an option in treating subretinal fluid after failure of other anti-VEGF agents associated with photodynamic therapy.
Palavras-chave
Age-related macular degeneration, Brolucizumab, Choroidal polypoidal vasculopathy, Photodynamic therapy, Subretinal fluid
Referências
- Yannuzzi L.A., Sorenson J., Spaide R.F., Lipson B., Idiopathic polypoidal choroidal vasculopathy (IPCV), Retina., 10, pp. 1-8, (1990)
- Koh A., Lee W.K., Chen L.J., Chen S.J., Hashad Y., Kim H., Et al., EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy, Retina., 32, pp. 1453-1464, (2012)
- Cheung C.M.G., Lai T.Y.Y., Teo K., Ruamviboonsuk P., Chen S.J., Kim J.E., Et al., Polypoidal choroidal vasculopathy - consensus nomenclature and non - indocyanine green angiograph diagnostic criteria from the Asia-Pacific Imaging Society PCV Workgroup, Ophthalmology., 128, pp. 443-452, (2021)
- Lee W.K., Iida T., Ogura Y., Chen S.J., Wong T.Y., Mitchell P., Et al., Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: A randomized clinical trial, JAMA Ophthalmol, 136, pp. 786-793, (2018)
- Lim T.H., Lai T.Y., Takahashi K., Wong T.Y., Chen L.J., Ruamviboonsuk P., Et al., Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial, JAMA Ophthalmol., 138, pp. 935-942, (2020)
- Gomi F., Oshima Y., Mori R., Kano M., Saito M., Yamashite A., Et al., Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan study, Retina., 35, pp. 1569-1576, (2015)
- Nguyen Q.D., Das A., Do D.V., Dugel P.U., Gomes A., Holz F.G., Et al., Brolucizumab: Evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration, Ophthalmology, 127, pp. 963-976, (2020)
- Augsburger M., Sarra G.M., Imesch P., Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration a comparative study, Graefes Arch Clin Exp Ophthalmol., 257, pp. 1889-1895, (2019)
- Ogura Y., Jaffe G.J., Cheung C.M., Kokame G.T., Iida T., Takahashi K., Et al., Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK, Br J Ophthalmol., 106, pp. 994-999, (2022)